A Study of Adjunctive Treatment of Aripiprazole in Schizophrenic Patients

This study has been completed.
Sponsor:
Collaborator:
Otsuka America Pharmaceutical
Information provided by:
Otsuka Pharmaceutical Development & Commercialization, Inc.
ClinicalTrials.gov Identifier:
NCT00300846
First received: March 8, 2006
Last updated: November 7, 2013
Last verified: June 2008
  Purpose

The purpose of this study is to evaluate the effect on patient weight of adjunctive therapy of aripiprazole with clozapine versus clozapine monotherapy, in schizophrenic patients who are not optimally controlled on clozapine.


Condition Intervention Phase
Schizophrenia
Drug: aripiprazole
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Comparative, Randomized, Double-Blind, Placebo Controlled Study on the Effect on Weight of Adjunctive Treatment With Aripiprazole in Patients With Schizophrenia.

Resource links provided by NLM:


Further study details as provided by Otsuka Pharmaceutical Development & Commercialization, Inc.:

Primary Outcome Measures:
  • Evaluate effect on patient weight of adjunctive therapy of aripiprazole with clozapine versus clozapine mono-therapy in schizophrenic patients who are not optimally controlled on clozapine.
  • The mean change from baseline in patient weight at Week 16 (LOCF) will be compared between the 2 groups.

Secondary Outcome Measures:
  • Efficacy (PANSS, CGI)
  • Effectiveness (IAQ, GAF)
  • Patient Reported Outcomes
  • Safety

Estimated Enrollment: 200
Study Start Date: December 2005
Study Completion Date: July 2007
Primary Completion Date: July 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: A1 Drug: aripiprazole
Tablets, Oral, 5 mg, 10 mg, 15 mg, once daily, 16 weeks followed by 12 weeks of Open-Label extension phase (optional).
Other Name: Abilify
Placebo Comparator: A2 Drug: Placebo
Tablets, Oral, 0 mg, once daily, 16 weeks followed by 12 weeks of Open-Label extension phase (optional)

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with schizophrenia treated with clozapine (200-900 mg/day), who gained at least 2.5 kg while on clozapine.

Exclusion Criteria:

  • Patients known to be allergic to aripiprazole
  • Hospitalized patients
  • Patients who have previously received study medication in an aripiprazole clinical study or who have participated in any clinical trial with an investigational agent within the past month.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00300846

  Hide Study Locations
Locations
Austria
Local Institution
Graz, Austria
Local Institution
Innsbruck, Austria
Local Institution
Wien, Austria
Czech Republic
Local Institution
Brno - Bohunice, Czech Republic
Local Institution
Hradec Kralove, Czech Republic
Local Institution
Litomerice, Czech Republic
Local Institution
Opava, Czech Republic
Local Institution
Praha, Czech Republic
Finland
Local Institution
Helsingin Kaupunki, Finland
Local Institution
Tampere, Finland
Local Institution
Turku, Finland
France
Local Institution
Brumath Cedex, France
Local Institution
Bully Les Mines, France
Local Institution
Clermont-Ferrand Cedex, France
Local Institution
Limoges Cedex, France
Local Institution
Lyon Cedex 08, France
Local Institution
Nimes, France
Local Institution
Paris Cedex 14, France
Local Institution
Rennex Cedex 7, France
Local Institution
Sotteville Les Rouen, France
Germany
Local Institution
Augsburg, Germany
Local Institution
Berlin, Germany
Local Institution
Duisburg, Germany
Local Institution
Haar, Germany
Local Institution
Heidelberg, Germany
Local Institution
Mannheim, Germany
Hungary
Local Institution
Budapest, Hungary
Local Institution
Szolnok, Hungary
Poland
Local Institution
Krakow, Poland
Local Institution
Leszno, Poland
Local Institution
Skorzewo, Poland
Local Institution
Torun, Poland
Local Institution
Warszawa, Poland
South Africa
Local Institution
Soweto, Gauteng, South Africa
Local Institution
Vereeniging, Gauteng, South Africa
Local Institution
Durban, Kwa Zulu Natal, South Africa
Local Institution
Bellville, Western Cape, South Africa
Local Institution
Cape Town, Western Cape, South Africa
Sweden
Local Institution
Bromma, Sweden
Local Institution
Falkoping, Sweden
Local Institution
Linkoping, Sweden
Local Institution
Lulea, Sweden
Local Institution
Malmo, Sweden
Local Institution
Solna, Sweden
Local Institution
Uppsala, Sweden
Local Institution
Varberg, Sweden
Local Institution
Vastra Frolunda, Sweden
Switzerland
Local Institution
Bern 60, Switzerland
Turkey
Local Institution
Antalya, Turkey
Local Institution
Istanbul, Turkey
Local Institution
Izmir, Turkey
United Kingdom
Local Institution
Exeter, Devon, United Kingdom
Local Institution
Teignmouth, Devon, United Kingdom
Local Institution
Welwyn Garden City, Hertfordshire, United Kingdom
Local Institution
Hull, North Yorkshire, United Kingdom
Local Institution
Dundee, Tayside, United Kingdom
Local Institution
London, United Kingdom
Sponsors and Collaborators
Otsuka Pharmaceutical Development & Commercialization, Inc.
Otsuka America Pharmaceutical
Investigators
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
No publications provided by Otsuka Pharmaceutical Development & Commercialization, Inc.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00300846     History of Changes
Other Study ID Numbers: CN138-170
Study First Received: March 8, 2006
Last Updated: November 7, 2013
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia and Disorders with Psychotic Features
Mental Disorders
Aripiprazole
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs

ClinicalTrials.gov processed this record on September 22, 2014